You are here

Lexaria Bioscience Corp.

Lexaria Bioscience Corp.
Listing Exchange: 
CSE
Status: 
Delisted
Industry: 
Diversified Industries
Symbol: 
LXX
CSE Index: 
Currency: 

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

 

You are here

Lexaria Bioscience Corp. (LXX)

SEDAR Information

Company Info

Address
#100 - 740 McCurdy Rd.,
Kelowna, BC V1X 2P7
Canada
Phone
1-250-765-6424
Fax
1-250-765-2599
Email
cbunka@lexariabioscience.com
Website
http://www.lexariabioscience.com
Listing date
Wednesday, October 28, 2009
Transfer Agent
Computershare Investor Services Inc.
Auditor
Davidson & Company LLP

Advertisement

Publicité

Capitalization

Issued & Outstanding: 
5,104,332
Reserved for Issuance: 
2,899,033
Total equity shares, as if converted: 
8,003,365

Company Officers

Chris Bunka, CEO
John Docherty, President
Greg Downey, CPA, CFO

Bulletins

08/07/2021

2021-0707 - Delist - Lexaria Bioscience Corp. (LXX)

le 8 juillet/July 2021

At the request of the company the common shares of Lexaria Bioscience Corp. will be delisted at market close on July 8, 2021.

The Company’s common shares will continue to trade on NASDAQ Capital Markets ("Nasdaq")

For more details see the company press release.

___________________________

Advertisement

Publicité

Latest CSE News